Jacobs Levy Equity Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
Other funds holding RARE
RI
FCM
Jacobs Levy Equity Management's RARE Position: Q2 2026 in Review
Jacobs Levy Equity Management increased its Ultragenyx Pharmaceutical (RARE) stake by 105% in Q2 2026, buying an estimated $37.5M and bringing the position to 2,939,719 shares worth $98.2M. The position accounts for 0.35% of the portfolio, ranked #70.
Jacobs Levy Equity Management first reported a position in RARE in Q1 2018 and has held it in 19 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Jacobs Levy Equity Management held 2,939,719 shares of Ultragenyx Pharmaceutical worth $98.2M as of Q2 2026.
- Jacobs Levy Equity Management bought 1,508,648 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $37.5M.
- Ultragenyx Pharmaceutical made up 0.35% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #70 holding.
- Jacobs Levy Equity Management first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 19 quarters since.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.